Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?

We precocious compiled a database of the 7 Best Psychedelic Stocks to Buy According to Analysts. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is 1 of the best psychedelic stocks on our list.

TheFly reported connected June 30 that VTGN announced topline findings from the PALISADE-4 Phase 3 proceedings evaluating intranasal fasedienol for the acute attraction of societal anxiousness disorder. The survey did not conscionable its superior endpoint, with fasedienol failing to show a statistically meaningful betterment compared with placebo based connected the alteration from baseline successful SUDS scores. The proceedings besides showed nary attraction vantage implicit placebo crossed secondary endpoints. However, fasedienol maintained a favorable information and tolerability profile, accordant with observations from earlier placebo-controlled objective studies.

Separately, earlier connected June 15, Vistagen Therapeutics, Inc. (NASDAQ:VTGN) reported its fiscal results for the fiscal twelvemonth ended March 31, 2026, on with a firm update. Research and improvement expenses accrued to $55.0 cardinal from $39.4 cardinal successful the anterior fiscal year, chiefly owed to activities supporting the PALISADE Program for fasedienol, manufacturing efforts, and improvement of the company's pherine candidates. General and administrative expenses roseate to $18.4 cardinal compared with $17.1 cardinal a twelvemonth earlier. The institution recorded a nett nonaccomplishment of $69.7 cardinal for the fiscal year, compared with $51.4 cardinal successful the erstwhile period. As of March 31, 2026, VTGN reported $45.4 cardinal successful cash, currency equivalents, and marketable securities, which it expects to enactment operations into 2027.

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is simply a clinical-stage neuroscience institution processing rapid-onset intranasal therapies for psychiatric disorders. It is often categorized among psychedelic stocks due to its absorption connected intelligence wellness innovation, though its proprietary therapies are not classical psychedelics.

While we admit the imaginable of VTGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.